The Clareon PanOptix lens is an intraocular lens that is implanted during cataract surgery after the cataract has been removed. In contrast to a standard monofocal lens, the PanOptix lens has the ability to treat presbyopia, a condition that prevents patients from seeing both far and near at the same time.
This lens is recently FDA approved and is the first to be classified as a trifocal intraocular lens. It is the next evolution in the treatment of presbyopia, building from its predecessor, the ReSTOR multifocal lens.
A multifocal lens gives patients the ability to see two distinct distances where images are in focus, such as far and near. In between the far and near focal points, images are not as clear. With the PanOptix lens, three distinct distances are in focus: far, intermediate, and near.
The PanOptix lens is made by Alcon on their AcrySof IQ platform, the same platform they use on their other intraocular lenses, including their monofocal lens, their toric lens, and their ReStor multifocal lens.
Just as with all multifocal lenses, there is an increased risk for halos and glare around lights at night. These side effects are typically well-tolerated and decrease with time.
The PanOptix lens also has a version that can correct astigmatism as well, called the PanOptix Toric lens.
When you come in for your cataract consultation, we can discuss whether the PanOptix lens is best suited for your individual needs.